Land: Irland
Sprog: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Dembrexine hydrochloride monohydrate
Boehringer Ingelheim Vetmedica GmbH
QR05CB90
Dembrexine hydrochloride monohydrate
5 milligram(s)/gram
Oral powder
POM: Prescription Only Medicine as defined in relevant national legislation
dembrexine hydrochloride
Authorised
1990-10-01
Health Products Regulatory Authority 23 November 2018 CRN008QMY Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Sputolosin Oral Powder 5 mg/g 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains: ACTIVE SUBSTANCE: Dembrexine hydrochoride monohydrate 5 mg (Equivalent to 4.372 mg of dembrexine per g.) For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral Powder. Fine, white and free-flowing. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES The product is indicated for the symptomatic treatment of acute, sub-acute and chronic respiratory disease of the upper and lower respiratory tract, where an abnormal amount of mucus of increased viscosity is present. 4.3 CONTRAINDICATIONS Do not use in animals known to be hypersensitive to the active substance. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None known. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS: None known. Health Products Regulatory Authority 23 November 2018 CRN008QMY Page 2 of 5 SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS: Care/precautions should be taken when using this product to avoid skin contact, eye contact and/or inhalation of the dust. Medical advice should be sought if you feel unwell after using this product. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) None known. 4.7 USE DURING PREGNANCY, LACTATION OR LAY Sputolosin has not been tested in pregnant mares, however, reproduction studies using dembrexine in laboratory animals show no teratogenic effect. Where Sputolosin has been administered to pregnant mares, no adverse effects have been reported. 4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTIONS None known. 4.9 AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE For oral administration in the food at a dose of 0.3 mg active ingredient per kg bodyweight twice daily; for example for a 500 kg horse, 30 g (6 le Læs hele dokumentet